Finnish consumer genetic testing firm Negen has turned to BC Platforms for analysis of raw genomic data for clinical reporting purposes, the companies announced recently.

Under terms of the new partnership, BC Platforms will run data collected by Negen through its data management system to inform Negen's risk-scoring algorithms. Further terms were not disclosed.

Negen offers specific tests for diabetes and cardiovascular disease risk based on genomic and lifestyle factors. These tests, as well as a general screening for rare hereditary conditions, are intended to inform clinicians in recommending treatments and lifestyle changes, the company said.

"This partnership will greatly increase the awareness and utility of our genetic risk-scoring tools and our automatized genetic data interpretation," Negen CEO Kimmo Aro said in a statement.